机译:非守门方Ret突变介导的塞培替替尼和Pralsetinib抗性的结构基础
Univ Texas MD Anderson Canc Ctr Div Canc Med Dept Invest Canc Therapeut Houston TX 77030 USA;
Univ Oklahoma Hlth Sci Ctr Peggy &
Charles Stephenson Canc Ctr Oklahoma City OK 73104 USA;
Univ Oklahoma Hlth Sci Ctr Dept Biochem &
Mol Biol Oklahoma City OK 73104 USA;
Univ Oklahoma Hlth Sci Ctr Peggy &
Charles Stephenson Canc Ctr Oklahoma City OK 73104 USA;
Univ Oklahoma Hlth Sci Ctr Peggy &
Charles Stephenson Canc Ctr Oklahoma City OK 73104 USA;
Univ Texas MD Anderson Canc Ctr Mol Diagnost Lab Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Endocrine &
Neoplasia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Endocrine &
Neoplasia Houston TX 77030 USA;
Univ Texas MD Anderson Canc Ctr Musculoskeletal Imaging Div Diagnost Imaging Houston TX 77030;
Univ Texas MD Anderson Canc Ctr Div Canc Med Dept Invest Canc Therapeut Houston TX 77030 USA;
Univ Oklahoma Hlth Sci Ctr Peggy &
Charles Stephenson Canc Ctr Oklahoma City OK 73104 USA;
Univ Oklahoma Hlth Sci Ctr Peggy &
Charles Stephenson Canc Ctr Oklahoma City OK 73104 USA;
Univ Oklahoma Hlth Sci Ctr Peggy &
Charles Stephenson Canc Ctr Oklahoma City OK 73104 USA;
RET-selective inhibitor; selpercatinib; pralsetinib; acquired resistance; mutation; crystal structure;
机译:L730V / I RET屋顶突变向Pralsetinib和Selpercatinib显示不同的活动
机译:用于选择性RET抑制剂Selpercatinib的定量生物分析测定和使用液相色谱 - 串联质谱法在小鼠血浆和组织匀浆中的PRALALETINIB
机译:RET溶剂前突变介导获得的耐受选择性RET抑制在RET驱动的恶性肿瘤中
机译:非本土侵袭植物肼(Hydrilla Verticillata)中的细胞突变介导的除草剂抗药物的演变
机译:与NAV1.7中突变相关的神经病疼痛综合征的结构基础
机译:L730V / I RET屋顶突变显示出普拉拉替尼和Selpercatinib的不同活动
机译:RET溶剂前突变介导获得的耐受选择性RET抑制在RET驱动的恶性肿瘤中
机译:自噬介导的抗辐射和apo2L / TRaIL治疗前列腺癌细胞的分子基础